Showing 18 results
Media ReleaseNovartis, Telstra Health and Monash University join forces to tackle Australia’s number one killer – heart diseaseA new partnership combining innovative medicines, digital healthcare, and clinical care for heart health, will see trial of new model of care for Aussies at risk of cardiovascular disease (CVD).…
Media ReleaseIndustry and clinical collaboration delivers screening pilot for heart wellness – yet more awareness and access needed to address Australia’s biggest killerOne Australian dies of cardiovascular disease (CVD) every 12 minutes.1,2 More proactive heart screening could help close a gap in our nation’s health system. Australians encouraged to get a heart…
Media ReleaseAustralia’s first gene therapy for babies born with spinal muscular atrophy (SMA), Zolgensma®, becomes available on the PBSZolgensma® becomes the first gene therapy in Australia for children under the age of 9 months with spinal muscular atrophy (SMA) to be listed on the Pharmaceutical Benefits Scheme (PBS)1 1 in 10,000…
Media ReleaseNovartis launches a ‘Wellness Day’ scheme – Encouraging employees to check-in on their health and set new community behavioursAll Novartis employees encouraged to take a day off work to schedule potentially life-saving health-screen check For every health screening completed – Novartis will donate $5 to both local cancer…
Featured NewsCoronavirus (COVID-19) Novartis Australia & New Zealand
Novartis in Australia and New Zealand continues to closely monitor and respond to the coronavirus (COVID-19) situation. Our priority is to ensure the health and safety of our people, patients, and healthcare professionals.
Media ReleaseCoronavirus (COVID-19) Novartis Australia & New ZealandNovartis in Australia and New Zealand continues to closely monitor and respond to the coronavirus (COVID-19) situation. Our priority is to ensure the health and safety of our people, patients, and…